Teva collaborating with Israeli academia on next-gen cancer antibodies

Teva Pharmaceuticals has signed a collaboration agreement with the commercial arm of the Weizmann Institute of Science to identify the next generation of innovative antibodies for cancer treatment.

The collaboration with the Yeda Research and Development Company follows an exhaustive process conducted by Teva to identify and engage in strategic collaborations with leading research teams at Israeli universities.

The team will be led by Dr Rony Dahan, a leading researcher in antibody and cancer immunology and immunotherapy studies, who joined the Weizmann Institute of Science two years ago after completing postdoctoral research at Rockefeller University.

Dr. Dahan and other leading researchers at Weizmann will work together with research teams at Teva, both in Israel and globally, to incorporate a number of research fields and groups that will focus on advanced immunological research, computational biology and advanced single-cell analysis capabilities.

“The decision to enhance collaboration with Israeli academia is due to the outstanding knowledge and innovation that characterise these institutions and its researchers, who are among the most talented worldwide,” said Dr Hafrun Fridriksdottir, Teva’s Executive Vice President of Global R&D.

Prof. Daniel Zajfman, President of the Weizmann Institute of Science, added: “This is very good news to the academy, the researches and the industry in Israel. There’s no doubt that this long-term investment will bear fruits and lead to breakthroughs in science and technology.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Sinovac secures $15m to accelerate COVID-19 vaccine development

Sinovac Biotech, a Chinese biopharma product provider, has secured $15 million to accelerate the development of a COVID-19 vaccine. The funds were invested by Advantech...

First generic remdesivir for COVID-19 treatment launched

Beximco Pharmaceuticals, the Bangladesh-based manufacturer of generic pharma products and APIs, has launched the world’s first generic remdesivir for treating COVID-19. Remdesivir is an antiviral...

Vividion Therapeutics partners with Roche on novel E3 ligases

San Diego biotech, Vividion Therapeutics, is collaborating with Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3...

Related news

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Sinovac secures $15m to accelerate COVID-19 vaccine development

Sinovac Biotech, a Chinese biopharma product provider, has secured $15 million to accelerate the development of a COVID-19 vaccine. The funds were invested by Advantech...